Colorado Patent of the Month – January 2025
CLEERLY INC is revolutionizing the way coronary artery disease is diagnosed and monitored through cutting-edge image analysis technology. Their latest invention leverages artificial intelligence and advanced image processing to transform CT scans into detailed, interactive 3D models of coronary arteries. This groundbreaking method provides a precise, non-invasive way to detect and visualize stenosis, atherosclerosis, and ischemia, allowing clinicians to assess heart health with unparalleled accuracy.
By utilizing machine learning algorithms trained on extensive datasets, CLEERLY’s system can automatically identify and quantify plaque buildup within the arteries. The technology presents this information through an intuitive graphical user interface, where users can explore a 3D artery tree, rotate it, and zoom in on affected areas. It also offers cross-sectional views and straightened vessel representations, making it easier for medical professionals to analyze blockages and predict potential complications.
One of the most significant advantages of this innovation is its potential to reduce unnecessary invasive procedures. Traditional methods often rely on angiography and stent placements, but recent studies suggest that medication and lifestyle changes may be equally effective for certain patients. CLEERLY’s AI-driven analysis provides a comprehensive, objective assessment of arterial health, empowering doctors to make more informed treatment decisions.
By bringing precision, automation, and deep insights to cardiovascular imaging, CLEERLY INC is not just improving diagnostics—it’s paving the way for a new era of personalized, non-invasive heart care. With its ability to track disease progression and guide treatment plans, this technology has the potential to save lives while reshaping the standard approach to heart disease management.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
